The goal of the Immunology and Cancer Immunotherapy Program (ICIP) is to unite through scholarly engagement and collaboration the efforts of basic and clinical immunologists to develop passive and active immunization strategies to treat cancer. ICIP adds value to NCCC by bringing together established and experienced NCI-funded, clinical trialists with NCI-funded cancer immunologists and immunologists to develop, design, execute, effectively monitor, and bring to fruition Dartmouth-initiated immunotherapy trials in renal cell carcinoma, melanoma, colon cancer, breast cancer, glioblastoma, and myeloma. ICIP has 18 members from 5 departments and more than $8.3 million in total funding, of which greater than $2.5 million derives from the NCI (31%). Since 2003, ICIP has published over 190 papers of which 8% involve intraprogrammatic collaborations and 13% involve inter-programmatic collaborations. Since 2003, the breadth and depth of the immunological expertise within the ICIP has been greatly strengthened and focused. ICIP has focused on the development of strategies to vaccinate against cancer, with the intent to move these strategies into clinical trials at Dartmouth. Both passive (T cell adoptive therapy) and active (dendritic cell (DC) and molecularly based) vaccines have been developed, some of which have entered clinical trials. The development and execution of these trials have greatly benefited from the CCSG-supported shared resources, especially Immune Monitoring. Enhanced ICIP focus and development has been facilitated by the strategic recruitment of key junior faculty by the NCCC. Their work, in turn, has been greatly facilitated by NCCC pilot project support, some of which was CCSG-supported. ICIP expertise now encompasses the scientific areas most important for the successful development of cancer vaccines. Establishment of a critical mass of experts in well-defined areas has enabled interactive """"""""Working Groups""""""""?confederations of ICIP experts with specific goals in the area of tumor immunotherapy. ICIP members study the natural immune responses to cancer?i.e., both the immunity and suppression elicited by a growing tumor. The role of DCs in mediating tumor suppression as well as tumor immunity is studied by a number of laboratories within the ICIP. Molecularly based vaccines to trigger robust cell-mediated immune responses to cancer are being developed for translation into humans. ICIP has formulated a vision for the present and future translation of cancer vaccines into humans.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dartmouth College
United States
Zip Code
Fang, Jun; Jia, Jinping; Makowski, Matthew et al. (2017) Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nat Commun 8:15034
Emond, Jennifer A; Tovar, Alison; Li, Zhigang et al. (2017) FTO genotype and weight status among preadolescents: Assessing the mediating effects of obesogenic appetitive traits. Appetite 117:321-329
Rapuano, Kristina M; Zieselman, Amanda L; Kelley, William M et al. (2017) Genetic risk for obesity predicts nucleus accumbens size and responsivity to real-world food cues. Proc Natl Acad Sci U S A 114:160-165
Carroll, A M; Cheng, R; Collie-Duguid, E S R et al. (2017) Fine-mapping of genes determining extrafusal fiber properties in murine soleus muscle. Physiol Genomics 49:141-150
Barr, Paul J; Forcino, Rachel C; Thompson, Rachel et al. (2017) Evaluating CollaboRATE in a clinical setting: analysis of mode effects on scores, response rates and costs of data collection. BMJ Open 7:e014681
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Rothwell, Simon; Cooper, Robert G; Lundberg, Ingrid E et al. (2017) Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis Rheumatol 69:1090-1099
Hampsch, Riley A; Shee, Kevin; Bates, Darcy et al. (2017) Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer. Oncotarget 8:21806-21817
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2017) Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium. Sci Rep 7:825
Melin, Beatrice S; Barnholtz-Sloan, Jill S; Wrensch, Margaret R et al. (2017) Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49:789-794

Showing the most recent 10 out of 1659 publications